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Background: Research on the human urine proteome may lay the foundation for the discovery of relevant disease
biomarkers. Post-translational modifications (PTMs) have important effects on the functions of protein biomarkers.
Identifying PTMs without enrichment adds no extra steps to conventional identification procedures for urine
proteomics. The only difference is that this method requires software that can conduct unrestrictive identifications
of PTMs. In this study, routine urine proteomics techniques were used to identify urine proteins. Unspecified PTMs
were searched by MODa and PEAKS 6 automated software, followed by a manual search to screen out in vivo PTMs
by removing all in vitro PTMs and amino acid substitutions.
Results: There were 75 peptides with 6 in vivo PTMs that were found by both MODa and PEAKS 6. Of these, 34
peptides in 18 proteins have novel in vivo PTMs compared with the annotation information of these proteins on
the Universal Protein Resource website. These new in vivo PTMs had undergone methylation, dehydration,
oxidation, hydroxylation, phosphorylation, or dihydroxylation.
Conclusions: In this study, we identified PTMs of urine proteins without the need for enrichment. Our investigation
may provide a useful reference for biomarker discovery in the future.
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Research on urine proteomics is important for the dis-
covery of disease biomarkers. Post-translational modifi-
cations (PTMs) of proteins regulate many physiological
functions. For example, acetylation is an important PTM
in metabolism regulation; phosphorylation is an import-
ant PTM in regulating enzyme activity in cellular signal-
ing pathways; oxidation is an important marker of
cellular aging; and methylation is an important PTM in
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reproduction in any medium, provided the orsubject to change, and these proteins may be potential
disease biomarkers. As reported previously, in patients
with diabetes, there are many advanced glycation end-
product peptides in urine [1,2]. The urine glycoproteomic
makeup is altered in patients with chronic kidney diseases
[3]. It has been shown that changes in osteopontin PTMs
in urine are related to kidney stones and ovarian cancer
[4,5]. Further, 2D-gels have demonstrated that there are
different molecular masses of the same protein in the
urine proteome [6]. Mass spectrometric immunoassays of
urine protein phenotypes have also revealed a novel gly-
cated end product of β-2-microglobulin [7].
Previous studies of urine protein PTMs have focused
primarily on glycosylation, in which the proteins were first
enriched via glycosylation and then identified as glycosy-
lated proteins [8-10]. With enrichment, PTMs can be
detected with high sensitivity. Research on other types of
PTMs has been limited by the lack of enrichment meth-
ods [11] because each method can only identify one type
of PTM. In the present study, instead of enriching for anyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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were used, and unspecified PTMs of urine proteins
were identified with the MODa and PEAKS 6 software.
Without enrichment, sensitivity to identify the PTMs is
low. Thus far, only one previous study on urine proteo-
mics reported the identification of phosphorylated pro-
teins without enrichment [12].
In conjunction with recent developments in PTM re-
search, dozens of expert algorithms have been created to
perform unrestrictive searches of protein PTMs that can
find almost all known PTMs and even novel PTMs. In this
study, the PTM algorithms in the software packages MODa
and PEAKS were used. MODa enables fast “multi-blind”
unrestrictive PTM searches with a speed that is an order of
magnitude faster than other existing approaches. It can also
identify any number of modifications on a single peptide.
In contrast to alternative approaches, MODa simultan-
eously uses multiple sequence tags from each MS/MS
spectrum and a dynamic programming algorithm to iden-
tify modifications between sequence tags matched to a
database peptide [13]. PEAKS PTM is an improved soft-
ware tool for peptide identification with unspecified PTMs.
The improvements in this software include a default setting
whereby the software considers all PTMs included in the
Universal Protein Resource (Unimod) database as variable
PTMs. Moreover, several search strategies are employed to
reduce the search time [14]. PEAKS PTM was included in
the PEAKS 6 software, which is the only commercial soft-
ware that can identify unspecified variable PTMs.
Results
PTMs identified by MODa and PEAKS 6
In this study, real in vivo PTMs were isolated from other
PTMs including in vitro PTMs and amino acid substitu-
tions by a manual search; the in vitro PTMs are mostly
created during experimental processes. In all, 39,144
spectra with 6,194 unique peptides and 1,994 proteins
were identified by MODa. Among these, 7,100 spectra
with 1,602 unique peptides and 734 proteins contained
PTMs with sizes accepted by the MODa search regardless
of the modification classification in Unimod. Within theseTable 1 A summary of the spectra, unique peptides, and prot
Software #PSMs(P




In vivo PTMs MODa 433
PEAKS 6 880




aIn PEAKS 6, a protein represents a group of proteins sharing all identified peptidesPTMs, 433 spectra with 169 unique peptides and 85 pro-
teins had in vivo PTMs. Furthermore, 47,857 spectra with
9,878 unique peptides and 1,606 protein groups were
identified by PEAKS 6. Among these, 20,329 spectra with
3,891 unique peptides and 1,578 proteins had PTMs with
sizes accepted by the PEAKS 6 search regardless of the
modification classification in Unimod. Within these
PTMs, 880 spectra with 254 unique peptides and 182 pro-
tein groups had in vivo PTMs. These findings are sum-
marized in Table 1.
In this search, 15 types of in vivo PTMs were identi-
fied by MODa, and 10 types of in vivo PTMs were iden-
tified by PEAKS 6 (Table 2).
The peptides with in vivo PTMs as found by MODa and
PEAKS 6 are presented in Additional file 1 and Additional
file 2. The whole urine peptides identified by MODa and
PEAKS 6 are presented in Additional file 3 and Additional
file 4.
PTMs identified by both MODa and PEAKS 6
The peptides with in vivo PTMs identified by both
MODa and PEAKS 6 were screened out because the
proteins identified as containing these peptides were
somewhat different between the two software packages.
Table 3 shows the peptides and corresponding proteins
identified by both software packages. Table 4 shows the
peptides identified by both software packages and the
corresponding proteins identified by either of the two.
The in vivo PTMs of the proteins identified by both soft-
ware packages were compared with the PTM informa-
tion in Uniprot, and some new PTMs were found.
The peptides identified by both software packages had
6 types of in vivo PTMs, which are shown in Table 5. In
PEAKS 6, one peptide can belong to several protein
groups. In contrast, in MODa, one peptide can only be-
long to one protein.
The spectra of the peptides with in vivo PTMs that
were identified most reliably by both software packages
are listed in Additional file 5, and only one spectrum per
peptide is listed.ein numbers
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This is the first study of its kind to identify post-
translational modifications in the urine proteome with-
out preferential enrichment, using a mixture of 12 human
urine samples (6 males and 6 females). The pooled sample
was used to identify as many PTMs as possible in a single
experiment. Because the original donors that provided the
urine samples may differ in gender, age and other medical
conditions, the PTMs in the urine proteomes are also
likely to be different among the individuals. The PTMs in
individual urine samples will be studied in the future.
Moreover, the reagents from the experimental procedures
including protein digestion may introduce many artifact
PTMs that are not endogenous to the samples. For ex-
ample, urea can cause the non-enzymatic modification of
carbamylation to certain proteins. The two software
packages identified both artifact PTMs and in vivo PTMs.
We manually excluded all possible artifact PTMs and
reported only the unequivocal in vivo PTMs.
Conclusions
In this study, we were able to identify all urine protein
PTMs without enrichment. Our investigation may pro-
vide a useful reference for biomarker discovery in the fu-
ture. As the technology and algorithms for conductingTable 2 A summary of the names, modification sizes, and mo
number of spectra, unique peptides, and proteins with in viv
In vivo PTMs Software △Mass














Lysine oxidation to aminoadipic semialdehyde −1
Deamidation 1
Didehydro −2
HexNAc PEAKS 6 203.08
Carboxylation 43.99
Persulfide 31.97
Hexose 162.05proteomic screens improve, more PTMs from the urine
proteome will likely be identified.
Materials and methods
Urine collection and preparation
Pooled urine was collected from 12 healthy donors (6 males
and 6 females). The donors (without medical condition and
eating behavior information) were between 20–40 years
old. The midstream of the urine was collected, and the
samples were stored at 4°C immediately. On the same day,
the urine was centrifuged at 3,000 × g for 10 min at 4°C.
After removing the precipitates, the supernatant was
added to three volumes of cold acetone. It was then incu-
bated at 4°C for 2 h, followed by centrifugation at
12,000 × g for 30 min. The precipitates were collected and
air-dried at room temperature. Afterwards, lysis buffer
(7 M urea, 2 M thiourea, 120 mM dithiothreitol, and
40 mM Tris) was added to resuspend the pellets, which
were then quantified by the Bradford method.
Protein digestion and peptide preparation
The urinary proteins were digested with trypsin (Trypsin
Gold, Mass Spec Grade, Promega, Fitchburg, Wisconsin)
by filter-aided sample preparation[15] using 10 kD Pall
filtration devices (Pall Corporation, Port Washington,dification sites of all the in vivo PTMs, as well as the
o PTMs
Position #PSMs #Peptides #Proteins
CDKNPRY 204 105 40
DKNPRY 224 139 71
CDEHKNSQRT 106 58 27
DEILNT, C-term, N-term 157 160 99
ST 26 19 14
STY 102 81 67
CLMPT 29 1 10
KPRY 32 48 30
DS 20 8 2
ST 192 154 57
STM(Protein N-term) 7 5 5
CST, Protein N-term 39 41 46
N 3 1 1
S 16 2 1
K 12 6 6
R 7 4 4
SY 6 1 1
NST 141 19 43
E 10 6 7
D 7 6 8
T, N-term 4 14 14
Table 3 The peptides with in vivo PTMs identified by both MODa and PEAKS 6 34 unique peptides of 18 proteins had
new PTMs (labeled by underline) compared to the Uniprot annotation information





R.SYSCQVTHEGSTVEK[Methylation].T sp|B9A064 192 ~ 206 Immunoglobulin lambda-like polypeptide 5 OS = Homo sapiens
GN = IGLL5 PE = 2 SV = 2
M.T[Acetylation]DGDYDYLIK.L sp|O00194 2 ~ 11 Ras-related protein Rab-27B OS = Homo sapiens GN = RAB27B PE = 1
SV = 4
K.GDAGPP[Hydroxylation]GPAGPAGPPGPI.G sp|P02452 836 ~ 862 Collagen alpha-1(I) chain OS = Homo sapiens GN = COL1A1 PE = 1
SV = 5K.GDAGPP[Hydroxylation]
GPAGPAGPPGPIGNVGAPGAK.G
R.EGAPGAEGSP[Hydroxylation]GR.D 1015 ~ 1026
K.DGEAGAQGPP[Hydroxylation]GPAGPAGER.G 613 ~ 631
R.DGNP[Hydroxylation]GSDGLPGR.D sp|P02461 1013 ~ 1024 Collagen alpha-1(III) chain OS = Homo sapiens GN = COL3A1 PE = 1
SV = 4R.DGNPGSDGLP[Hydroxylation]GR.D
R.TVAACNLPIVR[Methylation].G sp|P02760 283 ~ 293 Protein AMBP OS = Homo sapiens GN = AMBP PE = 1 SV = 1
K.N[Oxidation or Hydroxylation]
WGLSVYADKPETTK.E




51 ~ 60 Ig lambda-2 chain C regions OS = Homo sapiens GN = IGLC2 PE = 1
SV = 1
N.AMQVINNYQR[Methylation].R sp|P10153 53 ~ 62 Non-secretory ribonuclease OS = Homo sapiens GN = RNASE2 PE = 1
SV = 2
R.WGYSSTAITR[Methylation].Q sp|P10253 376 ~ 385 Lysosomal alpha-glucosidase OS = Homo sapiens GN = GAA PE = 1
SV = 4
K.TGPIGPQGAP[Hydroxylation]GK.P sp|P20908 1422 ~ 1433 Collagen alpha-1(V) chain OS = Homo sapiens GN = COL5A1 PE = 1
SV = 3
R.HS[Dehydration]PQEAPHVQYER.L sp|P26992 25 ~ 37 Ciliary neurotrophic factor receptor subunit alpha OS = Homo sapiens
GN = CNTFR PE = 1 SV = 2
R.LGPGMADICK[Methylation].N tr|B1AVU8 233 ~ 242 Proactivator polypeptide OS = Homo sapiens GN = PSAP PE = 4 SV = 1
K.AIPVAQDLNAPSDWDS[Phosphorylation]R.G tr|B2RDA1 190 ~ 206 `Osteopontin OS = Homo sapiens GN = SPP1 PE = 2 SV = 1
K.ANDES[Phosphorylation]NEHSDVIDSQELSK.V 236 ~ 254








K.YNSQNQSNNQFVLYR[Methylation].I 32 ~ 46
R.GPWCY[Oxidation or Hydroxylation]
VSGEAGVPEK.R




tr|B4DW75 3 ~ 15 EGF containing fibulin-like extracellular matrix protein 1






tr|C9JXD2 52 ~ 77 Osteopontin OS = Homo sapiens GN = SPP1 PE = 4 SV = 1 Epidermal




K.CIN[Oxidation or Hydroxylation]TEGGYVCR.C tr|E7EVD2 888 ~ 898
N.SSCVN[Oxidation or Hydroxylation]
TPGSFSCVCPEGFR.L
tr|E9PEA4 114 ~ 132 Uromodulin_ secreted form OS = Homo sapiens GN = UMOD PE = 4
SV = 1
R.D[Oxidation or Hydroxylation]WVSVVTPAR.D 409 ~ 418
R.DGPCGT[Dehydration]VLTR.N 419 ~ 428
R.MAETCVPVLR[Methylation].C 246 ~ 255
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Table 3 The peptides with in vivo PTMs identified by both MODa and PEAKS 6 34 unique peptides of 18 proteins had
new PTMs (labeled by underline) compared to the Uniprot annotation information (Continued)







K.FEHCNFNDVTTR[Methylation].L tr|E9PNW4 67 ~ 78 CD59 glycoprotein OS = Homo sapiens GN = CD59 PE = 4 SV = 1
R.LRENELT[Dehydration]YYCCK.K 79 ~ 90
R.LRENELTYYCCK[Methylation].K
R.YPNQVYYR[Methylation].P tr|F5GY30 96 ~ 103 Major prion protein OS = Homo sapiens GN = PRNP PE = 3 SV = 1
K.EGNPGPLGPIGP[dihydroxy]PGVR.G tr|H7C157 827 ~ 842 Collagen alpha-2(V) chain OS = Homo sapiens GN = COL5A2 PE = 4
SV = 1
bIf one peptide with in vivo PTMs was identified by both software packages, and the corresponding protein in MODa belonged to the same protein group in
PEAKS 6, then the protein in MODa belonged to a corresponding protein identified by both software packages.
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http://www.proteomesci.com/content/11/1/1New York). Briefly, after urine samples were loaded into
the filtration unit (200 μg per unit), 200 μL of UA buffer
(8 M urea in 0.1 M Tris–HCl, pH 8.5) was added to the
unit. After centrifuging the proteins at 13,000 × g for
20 min, repeat the UA wash. 200 μL of 50 mM NH4HCO3
was added, and the samples were centrifuged at 13,000 × g
for 20 min, repeat the NH4HCO3 wash. Afterwards, 100
μL of 20 mM dithiothreitol in 50 mM NH4HCO3 was
added to reduce the samples at 50°C for 1 h. Five microli-
ters of 1 M iodoacetamide was added to alkylate the sam-
ples in the dark at room temperature for 30 min. After
washing the filter twice with 50 mM NH4HCO3 at
13,000 × g for 20 min, trypsin (enzyme: protein ratio of
1:50) was added to digest the samples at 37°C overnight.
The filtration unit was centrifuged for 20 min to collect
the peptides, which were then desalted using a 1 mL
OASIS HLB cartridge (Waters, Milford, MA) according to
the manufacturer’s instructions. The elution was dried in
a SpeedVac system (Thermo Fischer Scientific) and stored
at −80°C until LC/MS/MS analysis.
LC/MS/MS methods
The lyophilized peptides were dissolved in 0.1% formic
acid and then separated by 2D LC/MS/MS using a strong
cation exchange column (150 mm × 320 mm inner diam-
eter, strong cation exchange resins from PolyLC Inc.,
Columbia, USA) and a reverse phase (RP) column
(150 mm× 100 mm id, Michrom Bioresources, Auburn,
California). One SCX elution method was used in which
the ammonia acetate pH gradients during the separation
and elution steps were 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, and
10. For RP separation, the eluted peptides were loaded
onto the column with buffer A (0.1% formic acid), and
the elution gradient was 5-30% buffer B (0.1% formic
acid + 99.9% ACN, flow rate: 0.5 μL/min). An LTQ-
Orbitrap Velos was operated in the data-dependent ac-
quisition mode with the XCalibur software. MS survey
scan data were acquired with the Orbitrap in the 300–2,000 m/z range with the resolution set to a value of
60,000. The 20 most intense ions per survey scan were
selected for CID fragmentation, and the resulting frag-
ments were analyzed with the linear trap (LTQ). Dynamic
exclusion was employed within 60 s to prevent repetitive
selection of the same peptide.
Data processing
Software and operating environment
MODa was obtained from the Division of Computer
Science and Engineering of Hanyang University in
Korea by email eunokpaek@hanyang.ac.kr. A trial
version of PEAKS 6 was downloaded from the Bio-
informatics Solutions website. The operating envir-
onment for MODa was a computer with 2 G RAM
and an IntelW Core™2 Duo CPU E6750 @2.66 GHz
2.00 GHz. PEAKS 6 was operated on a computer
with 16 G RAM and an IntelW XeonW CPU X5650
@2.67 GHz 2.66 GHz (2 processors).
File conversion
The RAW files were converted to MGF files by the MM
File Conversion software.
Database
The Uniprot human proteomics database released on 3/
21/2012.
Parameters for the MODa search
According to the README instruction in the software
folder, the parameters were set as follows:
PeptTolerance = 2.5: This parameter indicates the parent
mass tolerance in Daltons.
AutoPMCorrection = [0|1]: The default parameter
value is “0”, whereas “1” means that the program will
automatically find the optimal parent mass for the input
spectrum, regardless of the specified PeptTolerance.
Table 4 The peptides identified by both software packages, and the corresponding proteins identified by either of the
two software packages
Protein group (PEAKS PTM) cc Peptide (Both) Protein (MODa) c
5 K.AAT[Dehydration]GECTATVGK.R
8










500 K.CIN[Oxidation or Hydroxylation]HYGGYLCLPR.S tr|E9PKA3
90 K.CVN[Oxidation or Hydroxylation]HYGGYLCLPK.T
369















100 K.EGPVGLP[Oxidation or Hydroxylation]GIDGR.P tr|F5H299
249 K.GEVGPP[Oxidation or Hydroxylation]GPAGSAGAR.G tr|G8JLI4
K.GPP[Oxidation or Hydroxylation]GPQGPAGEQGPR.G
5 K.LGQSLDCN[Oxidation or Hydroxylation]AEVYVVPWEK.K
8
28 K.LHNLNSN[Oxidation or Hydroxylation]WFPAGSK.P tr|B3KTI1
37
31
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Table 4 The peptides identified by both software packages, and the corresponding proteins identified by either of the

















100 R.GLHGEFGLP[Oxidation or Hydroxylation]GPAGPR.G
R.GPP[Oxidation or Hydroxylation]GESGAAGPTGPIGSR.G
R.GPSGPP[Oxidation or Hydroxylation]GPDGNK.G











100 R.TGEVGAVGP[Oxidation or Hydroxylation]PGFAGEK.G tr|F5H299
R.TGEVGAVGPP[Oxidation or Hydroxylation]GFAGEK.G
90 R.TSSYLCQYQCVN[Oxidation or Hydroxylation]EPGK.F
13 R.VVAQGVGIPEDSIFT[Dehydration]MADR.G tr|B7Z8R6
16 S.LQCYNCPNPTADCK[Methylation].T tr|E9PI80
cIn PEAKS 6, one peptide can belong to several protein groups. In contrast, in MODa, one peptide can only belong to one protein.
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http://www.proteomesci.com/content/11/1/1FragTolerance = 0.5: This parameter indicates the frag-
ment ion mass tolerance in Daltons.
BlindMode = 2: This parameter indicates the number
of modifications per peptide, and '2' allows an arbitrary
number of modifications per peptide.
MinModSize = [−200], maxModSize = [+200]: This pa-
rameter indicates the minimum and maximum modifica-
tion size in Daltons (Da).Enzyme = Trypsin, KR/C: This parameter indicates the
reagent used for protein digestion as well as the cleavage
sites and amino acid terminus.
MissedCleavage = [2]: This parameter indicates the
number of allowed missed cleavage sites.
CysteineBlocking = Carbamidomethyl, 57: This parameter
indicates the chemical derived from a free cysteine by the
alkylation process and the mass of the chemical derivative.
Table 5 The in vivo PTMs identified by both software
packages and the number of peptides and proteins
In vivo PTMs #Peptides #Proteins
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http://www.proteomesci.com/content/11/1/1False discovery rate (FDR) ≤ 1%: This parameter
indicates the FDR of the Peptide-Spectrum Matches
(PSMs).
Parameters for the PEAKS 6 search
The search parameters were set as follows:
Parent Mass Error Tolerance: 10.0 ppm
Fragment Mass Error Tolerance: 0.1 Da
Precursor Mass Search Type: Monoisotopic
Max Missed Cleavages: 2
Non-specific Cleavage: 1
Fixed Modifications: Carbamidomethylation: 57.02
Variable Modifications:
Deamidation (NQ): 0.98; Oxidation (M): 15.99; Pyro-
glu from Q: -17.03; 4-hydroxynonenal (HNE): 156.12;
Acetylation(K): 42.01; Acetylation(N-term): 42.01; Acetyl-
ation(ProteinN-term): 42.01; Amidation: -0.98; and 669
more built-in modifications in PEAKS 6
Max variable PTM per peptide: 3.
Result filtration parameters: De novo score (ALC%)
threshold: 30; Peptide −10 lgP ≥ 17.5; Protein −10 lgP ≥
20; FDR (Peptide-Spectrum Matches): 1.00%.Manual search
For MODa, the observed modification size was matched
with the modification name and classification on the
Unimod website (http://www.unimod.org/modifications_-
list.php). The modification size was set as the average mass.
The modification size tolerance was set as 0.05 Daltons.
For PEAKS 6, the observed modification name was
matched with the modification classification on the
Unimod website. Some of the PTM classifications in
Unimod are Artefact, Post-translational, Chemical deriva-
tive, AAsubstitution, Pre-translational, and Multiple. The
PTMs that are classified as ‘Post-translational’ represent
in vivo PTMs.Additional files
Additional file 1: The peptides with in vivo PTMs as found by MODa.Additional file 2: The peptides with in vivo PTMs as found by PEAKS 6.
Additional file 3: The whole urine peptides identified by MODa.
Additional file 4: The whole urine peptides identified by PEAKS 6.
Additional file 5: The spectra of the peptides with in vivo PTMs
identified by both software packages.
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